John H. Alexander, MD, MHS
Credit: Duke University
Oral anti-coagulant (OAC)-naive individuals with atrial fibrillation (AF) showed a significantly smaller increase in stroke or systemic embolism with the use of asundexian versus apixaban than individuals with prior OAC exposure, according to new findings.1
This secondary analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic–Atrial Fibrillation (OCEANIC-AF) randomized clinical trial involved nearly 2500 OAC-naive patients and more than 12,000 OAC-experienced patients.
“These results suggest that patients with limited prior exposure to OACs may provide an important population for the evaluation of factor XI/XIa inhibitors as a new class of anticoagulants,” wrote the investigative team, led by John H. Alexander, MD, MHS, Duke Clinical Research…